Valentinuzzi et al. aimed to investigate whether immunotherapy [18F]FDG radiomics signature (iRADIOMICS) was able to predict response of metastatic NSCLC (stage IV) to pembrolizumab compared to the clinical standards (iRECIST and PD-L1 immunohistochemistry). Here, CD274 is linked to non-small cell lung carcinoma.